{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:05:59Z","timestamp":1794661559367,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Elranatamab, an approved bispecific antibody (BsAb) for relapsed\/refractory multiple myeloma, forms an immune synapse between the T-cell CD3 marker and B-cell maturation antigen (BCMA) on myeloma cells. Circulating soluble BCMA (sBCMA) is associated with disease burden and may reduce drug exposure, impacting efficacy. A quantitative systems pharmacology model that captures elranatamab\u2019s mechanism of action and disease dynamics was developed and calibrated to clinical datasets. Simulations explored model uncertainty and inter-patient variability with respect to biological, pharmacologic, and tumor-related components to inform clinical dose-response relationships and evaluate the effect of baseline sBCMA levels on dose and regimen. Model simulations supported 76\u2009mg weekly as the optimal regimen, including in patients with high sBCMA. A left shift in the dose-response curve among virtual responders supported maintenance of efficacy with less frequent dosing. This work exemplifies how mechanistic models may support BsAb dose and regimen justification within the framework of model-informed drug development.<\/jats:p>","DOI":"10.1038\/s41540-025-00585-z","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:43:45Z","timestamp":1756745025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma"],"prefix":"10.1038","volume":"11","author":[{"given":"Kamrine E.","family":"Poels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elmeliegy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hibma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Musante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerta","family":"Shtylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"585_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","volume":"111","author":"Y Furukawa","year":"2020","unstructured":"Furukawa, Y. & Kikuchi, J. Molecular basis of clonal evolution in multiple myeloma. Int. J. Hematol. 111, 496\u2013511 (2020).","journal-title":"Int. J. Hematol."},{"key":"585_CR2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"585_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 97, 1086\u20131107 (2022).","journal-title":"Am. J. Hematol."},{"key":"585_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0145-2126(12)70003-6","volume":"36","author":"I Borrello","year":"2012","unstructured":"Borrello, I. Can we change the disease biology of multiple myeloma?. Leuk. Res 36, S3\u2013S12 (2012).","journal-title":"Leuk. Res"},{"key":"585_CR5","doi-asserted-by":"crossref","unstructured":"Moreau, P. et al. Newly diagnosed myeloma in 2020. American Society of Clinical Oncology Educational Book, p. e144-e158 (2020).","DOI":"10.1200\/EDBK_280221"},{"key":"585_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bmt.2015.307","volume":"51","author":"RF Cornell","year":"2016","unstructured":"Cornell, R. F. & Kassim, A. A. Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 51, 479\u2013491 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"585_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu, B., Jiang, T. & Liu, D. BCMA-targeted immunotherapy for multiple myeloma. J. Hematol. Oncol. 13, 125 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"585_CR8","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1538-7445.AM2020-4557","volume":"80","author":"K Karwacz","year":"2020","unstructured":"Karwacz, K. et al. Abstract 4557: BCMA-CD3 bispecific antibody PF-06863135: Preclinical rationale for therapeutic combinations. Cancer Res 80, 4557\u20134557 (2020).","journal-title":"Cancer Res"},{"key":"585_CR9","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.3390\/ijms21155192","volume":"21","author":"HN Abramson","year":"2020","unstructured":"Abramson, H. N. B-cell maturation antigen (BCMA) as a target for new drug development in relapsed and\/or refractory multiple myeloma. Int. J. Mol. Sci. 21, 5192 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"585_CR10","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","volume":"18","author":"SH Panowski","year":"2019","unstructured":"Panowski, S. H. et al. Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol. Cancer Ther. 18, 2008\u20132020 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"585_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N. et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","journal-title":"Leukemia"},{"key":"585_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"YT Tai","year":"2019","unstructured":"Tai, Y. T. & Anderson, K. C. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin. Biol. Ther. 19, 1143\u20131156 (2019).","journal-title":"Expert Opin. Biol. Ther."},{"key":"585_CR13","unstructured":"FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma. 2023 09\/26\/2023 [cited 2024; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approvals-talvey-talquetamab-tgvs-relapsed-or-refractory-multiple."},{"key":"585_CR14","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3390\/cancers15061819","volume":"15","author":"D Swan","year":"2023","unstructured":"Swan, D. et al. Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety. Cancers15, 1819 (2023).","journal-title":"Cancers"},{"key":"585_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cts.12877","volume":"14","author":"PN Morcos","year":"2021","unstructured":"Morcos, P. N. et al. Quantitative clinical pharmacology of T-cell engaging bispecifics: current perspectives and opportunities. Clin. Transl. Sci. 14, 75\u201385 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"585_CR16","doi-asserted-by":"publisher","first-page":"2149053","DOI":"10.1080\/19420862.2022.2149053","volume":"15","author":"S Mak","year":"2023","unstructured":"Mak, S. et al. Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab. MAbs 15, 2149053 (2023).","journal-title":"MAbs"},{"key":"585_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47802-4","volume":"9","author":"O Milberg","year":"2019","unstructured":"Milberg, O. et al. A QSP model for predicting clinical responses to monotherapy, combination and sequential therapy following CTLA-4, PD-1, and PD-L1 checkpoint blockade. Sci. Rep. 9, 11286 (2019).","journal-title":"Sci. Rep."},{"key":"585_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12248-019-0332-z","volume":"21","author":"A Betts","year":"2019","unstructured":"Betts, A. et al. A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART\u00ae. AAPS J. 21, 66 (2019).","journal-title":"AAPS J."},{"key":"585_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1208\/s12248-021-00623-8","volume":"23","author":"RA Abbiati","year":"2021","unstructured":"Abbiati, R. A. et al. Quantitative systems pharmacology modeling of avadomide-induced neutropenia enables virtual clinical dose and schedule finding studies. Aaps J. 23, 103 (2021).","journal-title":"Aaps J."},{"key":"585_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtbi.2018.08.037","volume":"458","author":"J Gallaher","year":"2018","unstructured":"Gallaher, J. et al. Methods for determining key components in a mathematical model for tumor-immune dynamics in multiple myeloma. J. Theor. Biol. 458, 31\u201346 (2018).","journal-title":"J. Theor. Biol."},{"key":"585_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14726-5","volume":"12","author":"RE Abrams","year":"2022","unstructured":"Abrams, R. E. et al. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma. Sci. Rep. 12, 10976 (2022).","journal-title":"Sci. Rep."},{"key":"585_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"I Hosseini","year":"2020","unstructured":"Hosseini, I. et al. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. npj Syst. Biol. Appl. 6, 28 (2020).","journal-title":"npj Syst. Biol. Appl."},{"key":"585_CR23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/cts.13501","volume":"16","author":"ME Susilo","year":"2023","unstructured":"Susilo, M. E. et al. Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clin. Transl. Sci. 16, 1134\u20131148 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"585_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMp2109826","volume":"385","author":"M Shah","year":"2021","unstructured":"Shah, M. et al. The drug-dosing conundrum in oncology\u2014When less is more. N. Engl. J. Med. 385, 1445\u20131447 (2021).","journal-title":"N. Engl. J. Med."},{"key":"585_CR25","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis, N. J. et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat. Med. 29, 2570\u20132576 (2023).","journal-title":"Nat. Med."},{"key":"585_CR26","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"key":"585_CR27","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson, M. H. et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. HemaSphere 8, e136 (2024).","journal-title":"HemaSphere"},{"key":"585_CR28","doi-asserted-by":"publisher","first-page":"203636132312074","DOI":"10.1177\/20363613231207483","volume":"15","author":"T Rais","year":"2023","unstructured":"Rais, T., Khan, A. & Riaz, R. Elrexfio\u2122 (elranatamab-bcmm): The game-changer in treatment of multiple myeloma. Rare Tumors 15, 20363613231207483 (2023).","journal-title":"Rare Tumors"},{"key":"585_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent, S. A. et al. \u03b3-secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).","journal-title":"Nat. Commun."},{"key":"585_CR30","unstructured":"Lon, H. K. et al. Elranatamab Exposure-Efficacy Analysis in Patients With Relapsed or Refractory Multiple Myeloma: Insights From Pooled MagnetisMM Studies. (American Society of Hematology Annual Meeting, 2023)."},{"key":"585_CR31","doi-asserted-by":"publisher","first-page":"e07649","DOI":"10.1016\/j.heliyon.2021.e07649","volume":"7","author":"I Kareva","year":"2021","unstructured":"Kareva, I. et al. Bispecific antibodies: a guide to model informed drug discovery and development. Heliyon 7, e07649 (2021).","journal-title":"Heliyon"},{"key":"585_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1208\/s12248-016-0004-1","volume":"19","author":"A Tiwari","year":"2017","unstructured":"Tiwari, A. et al. Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling. Aaps J. 19, 510\u2013519 (2017).","journal-title":"Aaps J."},{"key":"585_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cpt.3487","volume":"117","author":"PH van der Graaf","year":"2025","unstructured":"van der Graaf, P. H. First-in-human dose selection for T-cell engaging bispecific antibodies. Clin. Pharm. Ther. 117, 11\u201313 (2025).","journal-title":"Clin. Pharm. Ther."},{"key":"585_CR34","doi-asserted-by":"publisher","first-page":"eaax8861","DOI":"10.1126\/scitranslmed.aax8861","volume":"11","author":"J Li","year":"2019","unstructured":"Li, J. et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci. Transl. Med. 11, eaax8861 (2019).","journal-title":"Sci. Transl. Med."},{"key":"585_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab, M. S. et al. Multiple myeloma. Lancet 374, 324\u2013339 (2009).","journal-title":"Lancet"},{"key":"585_CR36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie, B. G. M. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"585_CR37","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"585_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/psp4.12063","volume":"5","author":"R Allen","year":"2016","unstructured":"Allen, R., Rieger, T. & Musante, C. Efficient generation and selection of virtual populations in quantitative systems pharmacology models. CPT Pharmacomet. Syst. Pharmacol. 5, 140\u2013146 (2016).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"585_CR39","doi-asserted-by":"crossref","unstructured":"Cheng, Y. et al. Virtual Populations for Quantitative Systems Pharmacology Models, in Systems Medicine, J. P. F. Bai and J. Hur, Editors., p. 129-179 (Springer US, 2022).","DOI":"10.1007\/978-1-0716-2265-0_8"},{"key":"585_CR40","unstructured":"Mitchell, M. An Introduction to Genetic Algorithms. (The MIT Press, 1998)."},{"key":"585_CR41","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/1097-0142(197703)39:3<1077::AID-CNCR2820390311>3.0.CO;2-S","volume":"39","author":"JA Hokanson","year":"1977","unstructured":"Hokanson, J. A. et al. Tumor growth patterns in multiple myeloma. Cancer 39, 1077\u20131084 (1977).","journal-title":"Cancer"},{"key":"585_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0609.1996.tb01371.x","volume":"57","author":"TM Oivanen","year":"1996","unstructured":"Oivanen, T. M. Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma. Finnish Leuk. Group. Eur. J. Haematol. 57, 247\u2013253 (1996).","journal-title":"Finnish Leuk. Group. Eur. J. Haematol."},{"key":"585_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00505-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram, A. et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 11, 120 (2021).","journal-title":"Blood Cancer J."},{"key":"585_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis, S. et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 7, 644\u2013648 (2023).","journal-title":"Blood Adv."},{"key":"585_CR45","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt.1961","volume":"108","author":"A Betts","year":"2020","unstructured":"Betts, A. & van der Graaf, P. H. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin. Pharm. Ther. 108, 528\u2013541 (2020).","journal-title":"Clin. Pharm. Ther."},{"key":"585_CR46","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1021\/ja311795d","volume":"135","author":"EF Douglass Jr","year":"2013","unstructured":"Douglass, E. F. Jr et al. A comprehensive mathematical model for three-body binding equilibria. J. Am. Chem. Soc. 135, 6092\u20136099 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"585_CR47","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/cts.12662","volume":"12","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. A modeling framework to characterize cytokine release upon T-cell-engaging bispecific antibody treatment: methodology and opportunities. Clin. Transl. Sci. 12, 600\u2013608 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"585_CR48","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/psp4.12206","volume":"6","author":"B Ribba","year":"2017","unstructured":"Ribba, B. et al. Methodologies for quantitative systems pharmacology (QSP) models: design and estimation. CPT Pharmacomet. Syst. Pharm. 6, 496\u2013498 (2017).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"585_CR49","doi-asserted-by":"publisher","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball, K. et al. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs 15, 2181016 (2023).","journal-title":"MAbs"},{"key":"585_CR50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"585_CR51","first-page":"2018","volume":"132","author":"EJ Dettman","year":"1977","unstructured":"Dettman, E. J. et al. Expression of myeloma cell and soluble B-cell maturation antigen (BCMA) in relapsed and refractory multiple myeloma patients treated with GSK2857916 in BMA117159. Blood 132, 2018 (1977).","journal-title":"Blood"},{"key":"585_CR52","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cpt.2409","volume":"110","author":"G Ferron-Brady","year":"2021","unstructured":"Ferron-Brady, G. et al. Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed\/refractory multiple myeloma. Clin. Pharm. Ther. 110, 1282\u20131292 (2021).","journal-title":"Clin. Pharm. Ther."},{"key":"585_CR53","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2023-190341","volume":"142","author":"M Elmeliegy","year":"2023","unstructured":"Elmeliegy, M. et al. Soluble B-cell maturation antigen as a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from elranatamab (ELRA) magnetismm studies. Blood 142, 3345 (2023).","journal-title":"Blood"},{"key":"585_CR54","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","volume":"41","author":"SZ Usmani","year":"2023","unstructured":"Usmani, S. Z. et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. J. Clin. Oncol. 41, 8034\u20138034 (2023). (16_suppl).","journal-title":"J. Clin. Oncol."},{"key":"585_CR55","unstructured":"TECVAYLI (teclistimab-cqyv) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc."},{"key":"585_CR56","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448\u2013457 (2015).","journal-title":"Nat. Immunol."},{"key":"585_CR57","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8, 959\u2013970 (2016).","journal-title":"Immunotherapy"},{"key":"585_CR58","doi-asserted-by":"publisher","first-page":"818641","DOI":"10.3389\/fonc.2022.818641","volume":"12","author":"G Selvaggio","year":"2022","unstructured":"Selvaggio, G. et al. Computational analysis of cytokine release following bispecific T-cell engager therapy: applications of a logic-based model. Front. Oncol. 12, 818641 (2022).","journal-title":"Front. Oncol."},{"key":"585_CR59","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/psp4.13270","volume":"14","author":"N Braniff","year":"2025","unstructured":"Braniff, N. et al. An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints. CPT Pharmacomet. Syst. Pharmacol. 14, 268\u2013278 (2025).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"585_CR60","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2021-150519","volume":"138","author":"M Sebag","year":"2021","unstructured":"Sebag, M. et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood 138, 895\u2013895 (2021).","journal-title":"Blood"},{"key":"585_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJ Pessoa de Magalh\u00e3es","year":"2013","unstructured":"Pessoa de Magalh\u00e3es, R. J. et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98, 79\u201386 (2013).","journal-title":"Haematologica"}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00585-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00585-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00585-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:21:24Z","timestamp":1756902084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00585-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1038\/s41540-025-00585-z","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors were employees of Pfizer when the work took place.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}